Infinity Bio Partners with Austrian Institute of Technology for Expanded Antibody Profiling Access in Europe.

• PDS Biotech reports Q2 2025 financial results • Focus on transforming immune system's cancer targeting • Versatile-003 Phase 3 trial for PDS0101 in HPV16-positive head & neck cancer • Multiple abstracts presented at ASCO 2025 annual meeting • Conference call & webcast at 8:00 a.m. ET today • Company focused on late-stage immunotherapy development

PRINCETON, N.J., Aug. 13, 2025 — PDS Biotechnology Corporation (PDSB), a leading biotechnology company specializing in immunotherapies for cancer treatment, announced its second-quarter 2025 financial results and provided an update on its clinical programs. The company reported a net loss of $9.4 million, or $0.21 per basic and diluted share, for the three months ended June 30, 2025, compared to $8.3 million, or $0.23 per basic share and diluted share, for the same period in 2024. The increase in net loss was primarily due to higher net interest expenses, partially offset by lower personnel costs. Research and development expenses were $4.2 million for the quarter, compared to $4.5 million in the same period last year, reflecting lower personnel costs and higher manufacturing costs.

PDS Biotech's focus on developing immunotherapies positions it at the forefront of cancer treatment. The company's lead program, PDS0101 (Versamune HPV), is currently in a pivotal clinical trial for advanced HPV16-positive head and neck squamous cell cancers. The trial, known as Versatile-003, is designed to assess the safety and efficacy of the immunotherapy in combination with standard chemotherapy. The company also announced preclinical immune response data with a novel Infectimune-based universal flu vaccine, which was featured in presentations at the American Association of Immunologists’ IMMUNOLOGY2025™ Annual Meeting.

At the 2025 American Society of Clinical Oncology (ASCO) annual meeting, three abstracts on PDS0101 were presented, highlighting updated positive data from the Versatile-002 trial and additional trials evaluating the immunotherapy to treat head and neck cancers. The company's clinical and corporate update also announced the colorectal cancer cohort of a Phase 2 clinical trial with PDS01ADC, which met criteria for expansion to Stage 2 following positive Stage 1 results.

PDS Biotech's conference call and webcast today at 8:00 am Eastern Time will provide investors and financial professionals with an opportunity to gain insights into the company's financial performance and the progress of its clinical programs. The call will offer a chance to hear directly from the company's leadership about the future prospects of PDS Biotech and its impact on the cancer treatment landscape.

References:
[1] https://www.ainvest.com/news/pds-biotech-announces-q2-2025-financial-results-call-webcast-2508/
[2] https://www.marketbeat.com/instant-alerts/atb-cap-markets-has-positive-outlook-of-tsepd-q3-earnings-2025-08-04/
[3] https://www.morningstar.com/news/globe-newswire/9511505/pds-biotech-reports-second-quarter-2025-financial-results-and-provides-clinical-programs-update